BD Commits $110 Million to Boost Prefillable Syringe Manufacturing in Nebraska
BD announces a $110 million investment to expand prefillable syringe production in Columbus, Nebraska, aiming to enhance supply chain resilience for biologic and GLP-1 drugs, with operations set to begin by mid-2026.